Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Proteasome Structure01:17

The Proteasome Structure

2.1K
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
2.1K
The Proteasome02:18

The Proteasome

10.5K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.5K
The Proteasome01:13

The Proteasome

2.0K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
2.0K
The Proteasome02:18

The Proteasome

5.1K
5.1K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

2.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
2.0K
Protein Complex Assembly02:41

Protein Complex Assembly

17.1K
Proteins can form homomeric complexes with another unit of the same protein or heteromeric complexes with different types.  Most protein complexes self-assemble spontaneously via ordered pathways, while some proteins need assembly factors that guide their proper assembly. Despite the crowded intracellular environment, proteins usually interact with their correct partners and form functional complexes.
Many viruses self-assemble into a fully functional unit using the infected host cell to...
17.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In situ architecture of plasmodesmata in Physcomitrium patens resolved by cryo-electron tomography.

Nature plants·2026
Same author

Cryo-EM structure of locked spike glycoprotein from bat SARS-like coronavirus WIV1, molecular dynamics and biophysics across host range.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Metabolically regulated proteasome supramolecular organization in situ.

Cell·2026
Same author

NuMA promotes constitutive heterochromatin compaction by stabilizing linker histone H1 on chromatin.

Cell reports·2026
Same author

The subcellular architecture of <i>Paratrypanosoma confusum</i> revealed by CryoET: A window into early trypanosome evolution.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Author Correction: Structure and topography of the synaptic V-ATPase-synaptophysin complex.

Nature·2025

Related Experiment Video

Updated: Mar 27, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

Structure-Driven Developments of 26S Proteasome Inhibitors.

Paweł Śledź1, Wolfgang Baumeister1

  • 1Department of Molecular Structural Biology, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany;

Annual Review of Pharmacology and Toxicology
|January 8, 2016
PubMed
Summary

The 26S proteasome, a key cellular machine, is a therapeutic target for cancer and autoimmune diseases. This review details structural insights into developing inhibitors for both its 20S core and 19S regulatory particle.

Keywords:
19S regulatory particleAAA ATPasedeubiquitylationstructure-based drug design

More Related Videos

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.7K
Examining Proteasome Assembly with Recombinant Archaeal Proteasomes and Nondenaturing PAGE: The Case for a Combined Approach
09:57

Examining Proteasome Assembly with Recombinant Archaeal Proteasomes and Nondenaturing PAGE: The Case for a Combined Approach

Published on: December 17, 2016

7.0K

Related Experiment Videos

Last Updated: Mar 27, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K
Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.7K
Examining Proteasome Assembly with Recombinant Archaeal Proteasomes and Nondenaturing PAGE: The Case for a Combined Approach
09:57

Examining Proteasome Assembly with Recombinant Archaeal Proteasomes and Nondenaturing PAGE: The Case for a Combined Approach

Published on: December 17, 2016

7.0K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • The 26S proteasome is a large molecular complex central to the ubiquitin-proteasome pathway.
  • It is a validated therapeutic target for cancers and autoimmune diseases, with potential in antibacterial applications.
  • Current therapeutic strategies primarily target the 20S core, whose structure has been known for two decades.

Purpose of the Study:

  • To review the development of inhibitory molecules targeting both the 20S and 19S subunits of the 26S proteasome.
  • To provide a structural perspective on proteasome inhibitor development.
  • To highlight recent advancements in structure-based drug discovery for proteasome targets.

Main Methods:

  • Structural analysis of proteasome subunits.
  • Review of literature on proteasome inhibitors.
  • Structure-based drug design approaches.

Main Results:

  • The molecular architecture of the 19S regulatory particle has been poorly understood, hindering inhibitor development.
  • Recent progress in structural biology has improved understanding of the 19S subunit.
  • Structure-based drug discovery is advancing the development of inhibitors for both 20S and 19S proteasome targets.

Conclusions:

  • Targeting the 19S regulatory particle presents a promising avenue for novel therapeutic agents.
  • Continued structural studies and structure-based drug design will enhance the development of proteasome inhibitors.
  • Further research holds potential for improved treatments for various diseases by targeting the 26S proteasome.